May 05, 2020
Journal of Neuroinflammation Article Shows ZyVersa's Inflammasome Inhibitor, IC 100, Improves Functional Outcomes in an Animal Model of Multiple Sclerosis
Jan 30, 2020
ZyVersa Therapeutics Featured in Business Worldwide Magazine's Winter Edition as One of the 20 Most Innovative Companies to Watch
Jan 20, 2020
ZyVersa Therapeutics Releases Video Demonstrating How Inflammasomes Stimulate and Perpetuate Inflammation, and How a Novel Inflammasome Inhibitor, IC 100, Has Potential to Control Chronic Damaging Inflammation Associated with Inflammatory Diseases
Nov 13, 2019
ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the Stifel 2019 Healthcare Conference
Oct 28, 2019
ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the Inaugural Inflammasome Therapeutics Summit on October 30th, 2019
Sep 25, 2019
Interview with ZyVersa Therapeutics' CEO, Stephen C. Glover, Published in CEOCFO Magazine
Sep 19, 2019
ZyVersa Therapeutics Unveils a White Paper Fostering Education About Inflammasomes and Their Potential as a Promising Therapeutic and Diagnostic Target for Inflammatory Diseases
Sep 12, 2019
ZyVersa Therapeutics' Perspectives on Inflammasomes Reported in BIOCENTURY Innovations Article
Sep 05, 2019
ZyVersa Therapeutics Advances Development of Lead Inflammasome Inhibitor Candidate, IC 100
May 28, 2019
ZyVersa Therapeutics to Attend the World's Largest Biotechnology Partnering Event, BIO International (Philadelphia, June 3 - 6, 2019)
May 23, 2019
ZyVersa Therapeutics Announces Appointment of International Investor, Andrew (DW) Kim, to its Board of Directors
May 21, 2019
Experts on the Forefront of Inflammasome Research Will Serve on ZyVersa Therapeutics' Inaugural Immunology Scientific Advisory Board
May 15, 2019
ZyVersa Therapeutics Enhances Scientific Advisory Board with Three Esteemed Nephrologists
May 07, 2019
Jules A. Müsing, Former Senior Executive at Johnson & Johnson, Has Been Appointed Chairman of ZyVersa Therapeutics' Board of Directors